Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures

Neurotoxicology and Teratology

Volumn 46, Issue , 2014, Pages 49-56

  Rosenthaler, Sarah ^a   Pöhn, Birgit ^a   Kolmanz, Caroline ^a   Nguyen Huu, Chi ^a   Krewenka, Christopher ^a   Huber, Alexandra ^a   Kranner, Barbara ^a   Rausch, Wolf Dieter ^a   Moldzio, Rudolf ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cannabinoid receptors; Neural cell culture; Phytocannabinoids; Receptor binding affinity

Indexed keywords

CANNABICHROMENE; CANNABIDIOL; CANNABIDIVARIN; CANNABIGEROL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOL; GLUTATHIONE; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOL ACID; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BINDING AFFINITY; CELL VIABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; FEMALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL; NEUROBLASTOMA; TUMOR CELL LINE;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINERGIC NEURONS; GLUTATHIONE; HUMANS; MICE; NEUROBLASTOMA; NEURONS; RECEPTORS, CANNABINOID; TYROSINE 3-MONOOXYGENASE;

EID: 84908134717     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2014.09.003     Document Type: Article

References (35)

1. Borgelt L.M., Franson K.L., Nussbaum A.M., Wang G.S. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013, 2:195-209.
2. Borrelli F., Fasolino I., Romano B., Capasso R., Maiello F., Coppola D., et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013, 9:1306-1316.
3. Brown A.J. Novel cannabinoid receptors. Br J Pharmacol 2007, 152:567-575.
4. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002, 1:69-82.
5. Cheng Y., Hitchcock S.A. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 2007, 7:951-965.
6. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22(23):3099-3108.
7. Chinta S.J., Andersen J.K. Redox imbalance in Parkinson's disease. Biochim Biophys Acta 2008, 1780(11):1362-1367. [Review].
8. Colasanti B.K. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 1990, 4:259-269.
9. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909. [Review].
10. De Petrocellis L., Ligresti A., Moriello A.S., Allarà M., Bisogno T., Petrosino S., et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011, 163(7):1479-1494.
11. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglialactivation. J Neuroinflammation 2005, 2:29.
12. Elphick M.R., Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001, 1407:381-408.
13. Formukong E.A., Evans A.T., Evans F.J. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 1988, 4:361-371.
14. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., et al. Expression of central and peripheralcannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 1:54-61.
15. Hernández M., Berrendero F., Suárez I., García-Gil L., Cebeira M., Mackie K., et al. Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Res 2000, 857(1-2):56-65.
16. Hill A.J., Mercier M.S., Hill T.D., Glyn S.E., Jones N.A., Yamasaki Y., et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 2012, 8:1629-1642.
17. Howlett A.C. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005, (168):53-79. [Review].
18. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane Wa F.E.L.D.E.R.C.C., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54(2):161-202. [Review].
19. Howlett A.C., Padgett L.W., Shim J.Y. Cannabinoid agonist and inverse agonist regulation of g protein coupling. The cannabinoid receptors 2009, 176. Humana Press Verlag. P.H. Reggio (Ed.).
20. [http://www.bindingdb.org/bind/index.jsp- last access 29.06.2014]. http://pdsp.med.unc.edu/pdsp.php.
21. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 10:515-527.
22. Izzo A.A., Capasso R., Aviello G., Borrelli F., Romano B., Piscitelli F., et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol 2012, 4:1444-1460.
23. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl. 3):S26-S36. [discussion S36-8. Review].
24. Maldonado R., Berrendero F., Ozaita A., Robledo P. Neurochemical basis of cannabis addiction. Neuroscience 2011, 181:1-17.
25. Martin H.L., Teismann P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 2009, 23(10):3263-3272.
26. Mecha M., Torrao A.S., Mestre L., Carrillo-Salinas F.J., Mechoulam R., Guaza C. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis 2012, 3:e331.
27. Moldzio R., Radad K., Krewenka C., Kranner B., Duvigneau J.C., Wang Y., et al. Effects of epigallocatechingallate on rotenone-injured murine brain cultures. J Neural Transm 2010, 117(1):5-12.
28. Moldzio R., Pacher T., Krewenka C., Kranner B., Novak J., Duvigneau J.C., et al. Effects of cannabinoids δ(9)-tetrahydrocannabinol, δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+affected murine mesencephalic cultures. Phytomedicine 2012, 19(8-9):819-824.
29. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006, 13-8.
30. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 3:397-411.
31. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010, 17(14):1360-1381. [Review].
32. Ruhaak L.R., Felth J., Karlsson P.C., Rafter J.J., Verpoorte R., Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull 2001, 5:774-778.
33. Ryberg E., Larsson N., Sjögren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
34. Saito V.M., Rezende R.M., Teixeira A.L. Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol 2012, 2:159-166.
35. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58(9):1017-1030.